14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 MDGL stock ended at $229.84. This is 6.38% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 5.88% from a day low at $221.25 to a day high of $234.25.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Madrigal Pharmaceuticals, Inc. prices

Date Open High Low Close Volume
Jun 12, 2023 $266.05 $272.59 $261.18 $265.74 176 363
Jun 09, 2023 $268.82 $274.09 $263.74 $265.53 183 196
Jun 08, 2023 $275.01 $280.52 $268.50 $269.20 230 403
Jun 07, 2023 $272.60 $279.43 $271.70 $276.48 250 429
Jun 06, 2023 $267.25 $277.35 $263.56 $273.83 284 116
Jun 05, 2023 $258.66 $267.19 $258.17 $266.53 205 521
Jun 02, 2023 $268.61 $271.59 $255.41 $259.94 471 766
Jun 01, 2023 $278.00 $283.31 $266.32 $269.04 330 724
May 31, 2023 $279.48 $284.45 $276.55 $278.41 182 382
May 30, 2023 $288.29 $288.75 $279.01 $280.02 177 957
May 26, 2023 $286.76 $288.14 $278.90 $284.88 214 356
May 25, 2023 $293.27 $293.88 $277.06 $281.59 309 312
May 24, 2023 $280.68 $301.00 $280.68 $292.28 405 781
May 23, 2023 $285.59 $302.68 $280.09 $282.16 280 371
May 22, 2023 $277.00 $286.80 $274.02 $285.49 308 406
May 19, 2023 $278.57 $281.00 $273.45 $276.61 243 226
May 18, 2023 $276.65 $277.72 $270.22 $276.49 380 995
May 17, 2023 $290.40 $292.04 $276.07 $277.90 525 932
May 16, 2023 $280.82 $294.58 $270.74 $292.21 537 460
May 15, 2023 $295.83 $298.05 $289.43 $290.29 213 073
May 12, 2023 $293.65 $294.44 $285.48 $292.92 159 433
May 11, 2023 $289.19 $295.28 $283.01 $288.12 238 789
May 10, 2023 $301.85 $302.46 $290.18 $292.15 230 623
May 09, 2023 $306.26 $311.56 $269.03 $299.65 870 675
May 08, 2023 $308.18 $313.11 $301.45 $308.87 245 938
Click to get the best stock tips daily for free!

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,... MDGL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT